Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies

Version 1 : Received: 1 March 2021 / Approved: 2 March 2021 / Online: 2 March 2021 (14:14:38 CET)

A peer-reviewed article of this Preprint also exists.

Butowska, K.; Woziwodzka, A.; Borowik, A.; Piosik, J. Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies. Materials 2021, 14, 2135. Butowska, K.; Woziwodzka, A.; Borowik, A.; Piosik, J. Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies. Materials 2021, 14, 2135.

Journal reference: Materials 2021, 14, 2135
DOI: 10.3390/ma14092135

Abstract

Doxorubicin, a member of the anthracycline family, is a common anticancer agent often used as a first line treatment for the wide spectrum of cancers. Doxorubicin-based chemotherapy, although effective, is associated with serious side effects, such as irreversible cardiotoxicity or nephrotoxicity. Those often life-threatening adverse risks, responsible for the elongation of the patients' recuperation period and increasing medical expenses, have prompted the need for creating novel and safer drug delivery systems. Among many proposed concepts, polymeric nanocarriers are shown to be a promising approach, allowing for controlled and selective drug delivery simultaneously enhancing its activity towards cancerous cells and reducing toxic effects on healthy tissues. This article is a chronological examination of the history of the work progress on polymeric nanostructures, designed as efficient doxorubicin nanocarriers, with the emphasis on the main achievements of 2010-2020. Numerous publications have been reviewed to provide an essential summation of the nanopolymer types and their essential properties, mechanisms towards efficient drug delivery, as well as active targeting stimuli-responsive strategies that are currently utilized in the doxorubicin transportation field.

Keywords

doxorubicin; drug delivery; polymers; targeted therapy; anticancer treatment; controlled release

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.